Oncolys Biopharma Inc.
Overview
Oncolys BioPharma Inc. is a Tokyo-based biotechnology company established in March 2004, focusing on the development of innovative treatments for cancer and serious infectious diseases using virology-based drug discovery technologies. Their lead product, Telomelysin (OBP-301), is an oncolytic adenovirus immunotherapy currently in clinical development targeting various solid tumors.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Oncolys Biopharma Inc. in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Oncolys Biopharma Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.